X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs STERLING BIOTECH - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS STERLING BIOTECH NOVARTIS/
STERLING BIOTECH
 
P/E (TTM) x 348.2 -0.4 - View Chart
P/BV x 38.6 0.0 274,437.4% View Chart
Dividend Yield % 1.2 0.0 -  

Financials

 NOVARTIS   STERLING BIOTECH
EQUITY SHARE DATA
    NOVARTIS
Mar-18
STERLING BIOTECH
Dec-13
NOVARTIS/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs75811 7,219.0%   
Low Rs5793 17,029.4%   
Sales per share (Unadj.) Rs228.426.8 852.0%  
Earnings per share (Unadj.) Rs31.7-15.0 -212.2%  
Cash flow per share (Unadj.) Rs32.8-5.5 -599.7%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs297.154.9 541.4%  
Shares outstanding (eoy) m24.69267.87 9.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.90.3 1,129.0%   
Avg P/E ratio x21.1-0.5 -4,533.0%  
P/CF ratio (eoy) x20.4-1.3 -1,603.8%  
Price / Book Value ratio x2.20.1 1,776.6%  
Dividend payout %31.50-   
Avg Mkt Cap Rs m16,5051,862 886.6%   
No. of employees `0000.71.4 49.3%   
Total wages/salary Rs m1,445547 264.3%   
Avg. sales/employee Rs Th8,441.35,303.3 159.2%   
Avg. wages/employee Rs Th2,163.6403.8 535.8%   
Avg. net profit/employee Rs Th1,173.1-2,959.0 -39.6%   
INCOME DATA
Net Sales Rs m5,6397,181 78.5%  
Other income Rs m1,71843 4,033.6%   
Total revenues Rs m7,3577,223 101.9%   
Gross profit Rs m-63947 -6.6%  
Depreciation Rs m252,543 1.0%   
Interest Rs m554,377 1.3%   
Profit before tax Rs m1,575-5,931 -26.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m792-1,924 -41.1%   
Profit after tax Rs m784-4,007 -19.6%  
Gross profit margin %-1.113.2 -8.4%  
Effective tax rate %50.332.4 154.9%   
Net profit margin %13.9-55.8 -24.9%  
BALANCE SHEET DATA
Current assets Rs m9,52214,335 66.4%   
Current liabilities Rs m3,29649,809 6.6%   
Net working cap to sales %110.4-494.0 -22.3%  
Current ratio x2.90.3 1,003.8%  
Inventory Days Days37403 9.1%  
Debtors Days Days28171 16.7%  
Net fixed assets Rs m4655,432 0.1%   
Share capital Rs m123268 46.1%   
"Free" reserves Rs m7,21313,935 51.8%   
Net worth Rs m7,33614,701 49.9%   
Long term debt Rs m09,478 0.0%   
Total assets Rs m11,10573,988 15.0%  
Interest coverage x29.5-0.4 -8,306.4%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.50.1 523.2%   
Return on assets %7.60.5 1,508.1%  
Return on equity %10.7-27.3 -39.2%  
Return on capital %22.2-6.4 -345.9%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m611,860 3.3%   
Fx outflow Rs m3,63025 14,585.0%   
Net fx Rs m-3,5701,835 -194.5%   
CASH FLOW
From Operations Rs m1,6101,719 93.7%  
From Investments Rs m687-3,148 -21.8%  
From Financial Activity Rs m-2,6771,426 -187.7%  
Net Cashflow Rs m-380-3 11,164.7%  

Share Holding

Indian Promoters % 0.0 33.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 0.0 -  
FIIs % 1.6 9.9 16.2%  
ADR/GDR % 0.0 16.9 -  
Free float % 21.5 39.3 54.7%  
Shareholders   41,647 21,482 193.9%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   DIVIS LABORATORIES  WOCKHARDT LTD.  VENUS REMEDIES  PLETHICO PHARMA  GLENMARK PHARMA  

Compare NOVARTIS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY18); Net Profit Up 809.6% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, NOVARTIS has posted a net profit of Rs 265 m (up 809.6% YoY). Sales on the other hand came in at Rs 1 bn (down 13.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Sep 19, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS